Tables

TABLE 1 MOLECULES IN PIPELINE FOR ASTHMA 27
TABLE 2 MOLECULES IN PIPELINE FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER 33
TABLE 3 MOLECULES IN PIPELINE FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER 37
TABLE 4 MOLECULES IN PIPELINE FOR LUNG CANCER 42
TABLE 5 MOLECULES IN PIPELINE FOR IDOPATHIC PULMONARY FIBROSIS 47
TABLE 6 MOLECULES IN PIPELINE FOR IDOPATHIC PULMONARY FIBROSIS 49
TABLE 7 ABBVIE INC.: OFFERINGS 56
TABLE 8 ABBVIE INC: RECENT DEVELOPMENTS 56
TABLE 9 AMGEN INC.: OFFERINGS 61
TABLE 10 AMGEN INC.: RECENT DEVELOPMENTS 61
TABLE 11 ASTRA ZENCA PLC: OFFERINGS 68
TABLE 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS 69
TABLE 13 BAYER AG: OFFERINGS 74
TABLE 14 BAYER AG: RECENT DEVELOPMENTS 74
TABLE 15 BOEHRINGER INGELHEIM GMBH: OFFERINGS 79
TABLE 16 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 79
TABLE 17 BRISTOL-MYERS SQUIBB: OFFERINGS 84
TABLE 18 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT 84
TABLE 19 CELGENE CORPORATION: OFFERINGS 90
TABLE 20 CELGENE CORPORATION: RECENT DEVELOPMENTS 90
TABLE 21 DR. REDDY'S LABORATORIES LIMITED: PRODUCT OFFERINGS 94
TABLE 22 DR. REDDY'S LABORATORIES LIMITED: RECENT DEVELOPMENTS 94
TABLE 23 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 102
TABLE 24 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 102
TABLE 25 F. HOFFMANN-LA ROCHE LTD.: OFFERINGS 106
TABLE 26 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 107
TABLE 27 GLAXOSMITHKLINE PLC: OFFERINGS 112
TABLE 28 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 113
TABLE 29 JOHNSON & JOHNSON: PRODUCT OFFERINGS 118
TABLE 30 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 118
TABLE 31 MERCK & CO: PRODUCT OFFERINGS 125
TABLE 32 MERCK & CO: RECENT DEVELOPMENTS 125
TABLE 33 MYLAN N.V.: OFFERINGS 131
TABLE 34 MYLAN N.V.: RECENT DEVELOPMENT 131
TABLE 35 NOVARTIS AG: OFFERINGS 136
TABLE 36 NOVARTIS AG: RECENT DEVELOPMENTS 136
TABLE 37 PFIZER' INC.: OFFERINGS 141
TABLE 38 PFIZER' INC.: RECENT DEVELOPMENTS 142
TABLE 39 SANOFI: OFFERINGS 146
TABLE 40 SANOFI: RECENT DEVELOPMENTS 146
TABLE 41 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS 151
TABLE 42 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS 151
TABLE 43 VERTEX PHARMACEUTICALS INC.: OFFERINGS 156
TABLE 44 VERTEX PHARMACEUTICALS INC.: RECENT DEVELOPMENTS 156
TABLE 45 FIBROGEN' INC: OVERVIEW 161
TABLE 46 FIBROGEN INC: RECENT DEVELOPMENTS 161
TABLE 47 GILEAD SCIENCES INC.: OVERVIEW 162
TABLE 48 GILEAD SCIENCE INC: RECENT DEVELOPMENTS 162
TABLE 49 GLENMARK PHARMACEUTICAL LTD: OVERVIEW 164
TABLE 50 GLENMARK PHARMACEUTICAL LTD: RECENT DEVELOPMENTS 164
TABLE 51 ZIA LAB: OVERVIEW 165
TABLE 52 ZIA LAB: RECENT DEVELOPMENTS 165
TABLE 53 VECTURA GROUP PLC: OVERVIEW 166
TABLE 54 VECTURA GROUP AG: RECENT DEVELOPMENTS 166
TABLE 55 SOSEI GROUP CORPORATION: OVERVIEW 167
TABLE 56 SOSEI GROUP CORPORATION: RECENT DEVELOPMENTS 167
TABLE 57 ALMIRALL S.A: OVERVIEW 168
TABLE 58 ALMIRALL S.A.: RECENT DEVELOPMENTS 169
TABLE 59 BIOGEN INC: OVERVIEW 169
TABLE 60 BIOGEN INC: RECENT DEVELOPMENTS 170
TABLE 61 CHIESI FARMACEUTICI SPA: OVERVIEW 170
TABLE 62 CHIESI FARMACEUTICI SPA: RECENT DEVELOPMENTS 170
TABLE 63 TAKEDA PHARMACEUTICAL CO' LTD.: OVERVIEW 171
TABLE 64 TAKEDA PHARMACEUTICAL CO' LTD: RECENT DEVELOPMENTS 171
TABLE 65 SHIONOGI & CO.' LTD: OVERVIEW 172
TABLE 66 SHIONOGI & CO.' LTD: RECENT DEVELOPMENTS 172
TABLE 67 SUN PHARMACEUTICALS: OVERVIEW 173
TABLE 68 ZIA LAB: RECENT DEVELOPMENTS 174
TABLE 69 UNITED THERAPEUTICS CORP.: OVERVIEW 174
TABLE 70 PROMETIC LIFE SCIENCES INC.: OVERVIEW 175
TABLE 71 PROMETIC LIFE SCIENCES INC.: RECENT DEVELOPMENTS 176
TABLE 72 DAIICHI SANKYO' INC.: RECENT DEVELOPMENTS 176
TABLE 73 AUROBINDO PHARMA LTD: OVERVIEW 177
TABLE 74 AUROBINDO PHARMA LTD: RECENT DEVELOPMENTS 177
TABLE 75 EISAI CO.' LTD: OVERVIEW 179
TABLE 76 EISAI CO.' LTD: RECENT DEVELOPMENTS 179
TABLE 77 SHIRE PLC: OVERVIEW 180
TABLE 78 SHIRE PLC: RECENT DEVELOPMENTS 180
TABLE 79 GNI GROUP LTD: OVERVIEW 182
TABLE 80 GNI GROUP LTD: RECENT DEVELOPMENTS 182
TABLE 81 MEDICINOVA INC: OVERVIEW 183
TABLE 82 MEDICINOVA INC: RECENT DEVELOPMENTS 183
TABLE 83 ONO PHARMACEUTICAL CO.' LTD: OVERVIEW 184
TABLE 84 ONO PHARMACEUTICAL CO.' LTD: RECENT DEVELOPMENTS 184
TABLE 85 PROMEDIOR' INC: OVERVIEW 185
TABLE 86 PROMEDIOR INC: RECENT DEVELOPMENTS 185
TABLE 87 SUMITOMO DAINIPPON PHARMA CO.' LTD: OVERVIEW 186
TABLE 88 SUMITOMO DAINIPPON PHARMA CO.' LTD: RECENT DEVELOPMENTS 186

?

LIST OF FIGURE

Charts

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016) 16
CHART 2 PHARMACEUTICAL MOLECULLES IN DEVELOPMENT FOR NON-COMMUNICABLE DISEASES (NCDS) 17
CHART 3 R&D INVESTMENT BY TOP 10 COMPANIES ($BN) 18
CHART 4 PHARMACEUTICAL DRUGS BY SALES' 2017 19
CHART 5 PEST ANALYSIS OF RESPIRATORY DRUGS MARKET 20
CHART 6 RESEARCH METHODOLOGY OF RESPIRATORY DRUGS PIPELINE 22
CHART 7 NUMBER OF LARGE MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS 26
CHART 8 NUMBER OF SMALL MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS 26
CHART 9 RESPIRATORY PRODUCT PIPELINE BASED ON THE MOLECULE TYPE 27
CHART 1 RESPIRATORY DRUGS MARKET BY APPLICATION SEGMENTATION' 2017 VS 2024 (%) 28
CHART 2 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR ASTHMA 33
CHART 3 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER 37
CHART 4 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER 42
CHART 5 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR LUNG CANCER 48
CHART 6 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR LUNG CANCER 50
CHART 7 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR IDOPATHIC PULMONARY FIBROSIS 52
CHART 8 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR OTHER RESPIRATORY DISEASES 54
CHART 9 ABBVIEE INC: OVERVIEW SNAPSHOT 60
CHART 10 ABBVIEE INC.: GEOGRAPHIC PRESENCE 61
CHART 11 ABBVIE INC.: SWOT ANALYSIS 62
CHART 12 AMGEN INC.: OVERVIEW SNAPSHOT 65
CHART 13 AMGEN INC.: GEOGRAPHIC PRESENCE 66
CHART 14 AMGEN: SWOT ANALYSIS 68
CHART 15 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT 71
CHART 16 ASTRA ZENCA PLC: BUSINESS UNITS 73
CHART 17 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE 74
CHART 18 ASTRA ZENCA PLC: SWOT ANALYSIS 75
CHART 19 BAYER AG: OVERVIEW SNAPSHOT 77
CHART 20 BAYER AG: BUSINESS UNITS 77
CHART 21 BAYER GA: GEOGRAPHICAL PRESENCE 78
CHART 22 BAYER AG: SWOT ANALYSIS 79
CHART 23 BOEHRINGER INGELHEIM GMBH: OVERVIEW SNAPSHOT 81
CHART 24 BOEHRINGER INGELHEIM GMBH: BUSINESS UNITS 82
CHART 25 BOEHRINGER INGELHEIM GMBH: GEOGRAPHIC PRESENCE 84
CHART 26 BOEHRINGER INGELHEIM GMBH: SWOT ANALYSIS 84
CHART 27 BRISTOL-MYERS SQUIBB.: OVERVIEW SNAPSHOT 88
CHART 28 BRISTOL-MYERS SQUIBB.: BUSINESS SEGMENTS 89
CHART 29 BRISTOL-MYERS SQUIBB.: GEOGRAPHIC PRESENCE 90
CHART 30 BRISTOL-MYERS SQUIBB.: SWOT ANALYSIS 90
CHART 31 CELGENE CORPORATION: OVERVIEW SNAPSHOT 93
CHART 32 CELGENE CORPORATION: GEOGRAPHIC PRESENCE 93
CHART 33 CELGENE CORPORATION: SWOT ANALYSIS 94
CHART 34 DR. REDDY'S LABORATORY LIMITED: OVERVIEW SNAPSHOT 100
CHART 35 DR. REDDY'S LABORATORY LIMITED: BUSINESS UNITS 100
CHART 36 DR. REDDY'S LABORATORY LIMITED: GEOGRAPHICAL PRESENCE 102
CHART 37 DR. REDDY'S LABORATORY LIMITED: SWOT ANALYSIS 103
CHART 38 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT 105
CHART 39 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT 105
CHART 40 ELI LILLY & COMPANY LTD.: GEOGRAPHIC REVENUE 106
CHART 41 ELI LILLY & COMPANY LTD.: SWOT ANALYSIS 107
CHART 42 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 108
CHART 43 F. HOFFMANN.LA ROCHE LTD.: BUSINESS UNITS 111
CHART 44 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE 112
CHART 45 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 113
CHART 46 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT 114
CHART 47 GLAXOSMITHKLINE PLC: BUSINESS UNITS 117
CHART 48 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE 118
CHART 49 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 119
CHART 50 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 122
CHART 51 JOHNSON & JOHNSON: BUSINESS UNITS 123
CHART 52 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 124
CHART 53 JOHNSON & JOHNSON: SWOT ANALYSIS 126
CHART 54 MERCK & CO: OVERVIEW SNAPSHOT 128
CHART 55 MERCK & CO: BUSINESS UNITS 129
CHART 56 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 130
CHART 57 MERCK & CO: SWOT ANALYSIS 131
CHART 58 MYLAN N.V. OVERVIEW SNAPSHOT 134
CHART 59 MYLAN N.V.: BUSINESS SEGMENTS 134
CHART 60 MYLAN N.V.: GEOGRAPHIC PRESENCE 136
CHART 61 MYLAN N.V.: SWOT ANALYSIS 137
CHART 62 NOVARTIS AG: OVERVIEW SNAPSHOT 139
CHART 63 NOVARTIS AG: BUSINESS UNITS 139
CHART 64 NOVARTIS AG: GEOGRAPHICAL PRESENCE 140
CHART 65 NOVARTIS AG: SWOT ANALYSIS 141
CHART 66 PFIZER' INC.: OVERVIEW SNAPSHOT 145
CHART 67 PFIZER INC.: BUSINESS UNITS 146
CHART 68 PFIZER INC.: GEOGRAPHIC PRESENCE 146
CHART 69 PFIZER INC: SWOT ANALYSIS 147
CHART 70 SANOFI SA: OVERVIEW SNAPSHOT 149
CHART 71 SANOFI SA: SEGMENTATION 150
CHART 72 SANOFI SA: GEOGRAPHIC REVENUE 151
CHART 73 SANOFI SA: SWOT ANALYSIS 151
CHART 74 TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW SNAPSHOT 154
CHART 75 TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS UNITS 155
CHART 76 TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL PRESENCE 155
CHART 77 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 156
CHART 78 VERTEX PHARMACEUTICALS INC.: OVERVIEW SNAPSHOT 160
CHART 79 VERTEX PHARMACEUTICALS INC.: GEOGRAPHICAL PRESENCE 161
CHART 80 VERTEX PHARMACEUTICALS INC.: SWOT ANALYSIS 162